Organizations like yours are familiar to us. We are chemists, engineers, molecular biologists, researchers, and scientists who combine our technical understanding with legal, regulatory, and compliance excellence to provide you with well-informed counsel – from your patent portfolio development, protection, and monetization strategies to market entry and exit strategies.
Whether you are an inventor, start-up, venture capitalist, investor, Fortune 50 or Fortune 500 company, or research institution we help people like you on all aspects of pharmaceuticals, biotechnology and medical devices. We understand that regulatory and compliance will dominate your thinking – and can help you meet your requirements on every issue from M&A to tax, HR and real estate.
We know that often in this industry, time is of the essence, and we are proud that we continually demonstrate that we can work at speed without compromising on efficiency. This is demonstrated by our looking at patents for potential vaccines and detection methods, as well as dealing with urgent approval for medical devices and personal protective equipment.
Whatever your background, we can help you commercialize your inventions, protect key intellectual property and structure your business and partnerships to best enable you to bring the next generation of medicines, products and services to market.
Our Life Sciences and Healthcare capability in Ireland
Ireland generates an enormous output in the life sciences sector, from the world’s largest corporates to a vibrant indigenous community. Ireland is home to 14 of the world’s top 15 Medical Technology companies and 9 of the top 10 Pharma companies. With offices in Dublin and Belfast, we present you with an all-island, cross-departmental, full legal service offering. Our life sciences team are able to help you with a range of intellectual property licensing to product liability, from regulatory advices to navigating the local healthcare ecosystem. Our cross-disciplinary team can advise you at all phases of development and has experience in every aspect of the life sciences sector.
Our recent experience includes advising:
- an Irish medical device manufacturer which is a world leader in nebulizer technology on its arrangements with one of Chinas largest life sciences enterprises for the deployment of the clients’ proprietary nebulizer technology for the use in the inhaled delivery of a Covid-19 vaccine
- a locally-based manufacturer of surgical wound closure devices in connection the clinical trial process for its latest devices. The clinical trials were conducted in a number of medical institutions across a number of EU jurisdictions
- a clinical diagnostics client on its most recent fundraising including an award of significant European Union Funding for development and commercialization of its rapid testing products for use in respect of detecting presence of the Covid-19 virus
- members of a multimember US specialized Private Equity Group on a significant Series B Investment Round in an Irish based device manufacturing enterprise. The investment round involved investment by strategic investment funds and industry participants from across the globe
- a major international generic drug manufacturer on its local establishment including the construction of its European Manufacturing Headquarters and business transfer to the new faciltity
Key contacts
Latest Insights
- legal updatesThe EDPB’s new scientific research guidelines: a welcome route map, but no shortcut for “research” by assertion
- legal updatesHong Kong: Open consultation on listing reforms
- legal updatesEU Legislation Roundup: February 2026
- legal updatesHow statutory warranty laws differ across jurisdictions
Latest News
- firm newsEversheds Sutherland Advises The Centurion Foundation on Completed Acquisition of Roger Williams Medical Center and Fatima Hospital
- client newsEversheds Sutherland advises on £5.2bn disposal of Barchester Healthcare
- client newsEversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical Care
- firm newsEversheds Sutherland continues IP and Life Sciences practice expansion with European lateral partner hire
legal updates
April 28, 2026
The EDPB’s new scientific research guidelines: a welcome route map, but no ...
legal updates
April 14, 2026
Hong Kong: Open consultation on listing reforms
legal updates
March 05, 2026
EU Legislation Roundup: February 2026
legal updates
March 02, 2026
How statutory warranty laws differ across jurisdictions
firm news
March 20, 2026
Eversheds Sutherland Advises The Centurion Foundation on Completed Acquisit...
client news
November 06, 2025
Eversheds Sutherland advises on £5.2bn disposal of Barchester Healthcare
client news
September 06, 2024
Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of C...
firm news
November 03, 2022
Eversheds Sutherland continues IP and Life Sciences practice expansion with...